MX2023007135A - Detección y tratamiento de la fiebre de las montañas rocosas. - Google Patents

Detección y tratamiento de la fiebre de las montañas rocosas.

Info

Publication number
MX2023007135A
MX2023007135A MX2023007135A MX2023007135A MX2023007135A MX 2023007135 A MX2023007135 A MX 2023007135A MX 2023007135 A MX2023007135 A MX 2023007135A MX 2023007135 A MX2023007135 A MX 2023007135A MX 2023007135 A MX2023007135 A MX 2023007135A
Authority
MX
Mexico
Prior art keywords
treatment
rocky mountain
spotted fever
mountain spotted
fever detection
Prior art date
Application number
MX2023007135A
Other languages
English (en)
Inventor
Clever Madrid
Anton Mestek
Joshua Michael Boucher
Jesse Stephen Buch
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Publication of MX2023007135A publication Critical patent/MX2023007135A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/29—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Richettsiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

En la presente descripción se proporcionan composiciones y métodos para la detección y el tratamiento de la fiebre de las Montañas Rocosas ("RMSF"). Las composiciones detectan específicamente Rickettsia rickettsii y no reaccionan de manera cruzada con otras especies de Rickettsia, lo que proporciona un diagnóstico rápido y preciso de RMSF.
MX2023007135A 2020-12-17 2021-12-17 Detección y tratamiento de la fiebre de las montañas rocosas. MX2023007135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063126756P 2020-12-17 2020-12-17
PCT/US2021/064065 WO2022133233A2 (en) 2020-12-17 2021-12-17 Rocky mountain spotted fever detection and treatment

Publications (1)

Publication Number Publication Date
MX2023007135A true MX2023007135A (es) 2023-08-25

Family

ID=82023475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007135A MX2023007135A (es) 2020-12-17 2021-12-17 Detección y tratamiento de la fiebre de las montañas rocosas.

Country Status (7)

Country Link
US (1) US20220196672A1 (es)
EP (1) EP4262860A2 (es)
JP (1) JP2024500758A (es)
KR (1) KR20230121863A (es)
CA (1) CA3202186A1 (es)
MX (1) MX2023007135A (es)
WO (1) WO2022133233A2 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842473B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2019027670A1 (en) * 2017-07-31 2019-02-07 Kansas State University Research Foundation VACCINES AGAINST DISEASES TRANSMITTED BY TICK

Also Published As

Publication number Publication date
US20220196672A1 (en) 2022-06-23
KR20230121863A (ko) 2023-08-21
CA3202186A1 (en) 2022-06-23
WO2022133233A3 (en) 2022-09-22
EP4262860A2 (en) 2023-10-25
JP2024500758A (ja) 2024-01-10
WO2022133233A2 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
AR048031A1 (es) Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes
CO2021015520A2 (es) Combinación de marcador de mirna y kit para el diagnóstico del cáncer gástrico
Bartolini et al. Role of gut microbiota-immunity axis in patients undergoing surgery for colorectal cancer: focus on short and long-term outcomes
Krajewski et al. Are there differences in toxicity and efficacy between various bacillus Calmette-Guerin strains in bladder cancer patients? Analysis of 844 patients
WO2021162981A3 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
EP3980050A4 (en) <SMALLCAPS/>? ? ?p PNEUMONIA? ? ? ? METHOD OF TREATMENT OF PATIENTS WITH AN IMMUNOGENIC COMPOSITION PROTECTING AGAINST SEROTYPE 29
WO2018038352A3 (ko) 치매진단용 자가항체 바이오마커 및 이를 이용한 치매진단 방법
EA202192925A1 (ru) Твердые формы ингибитора glyt1
NO20075597L (no) En ultralydpaviselig intrauterinsystem og en fremgangsmate for a forbedre ultralydpavisning
Robinson et al. Review‐Helicobacter, inflammation, immunology and vaccines
JP2020502198A5 (es)
MX2023007135A (es) Detección y tratamiento de la fiebre de las montañas rocosas.
WO2020106393A3 (en) Skeletal maturity determination using radiographs of portions of a hand
MX2018003454A (es) Composiciones y metodos para diagnosticar la enfermedad de lyme y para predecir la eliminacion de las espiroquetas de la enfermedad de lyme despues del tratamiento.
NZ764338A (en) Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
SE1750203A1 (en) Novel peptides and their use in diagnosis
EA202190755A1 (ru) Агенты для терапии и диагностики рака
MX2019005940A (es) Biomarcadores relacionados a cancer.
Rüdiger et al. Guided tissue regeneration using a polylactic acid barrier. Part I: Environmental effects on bacterial colonization
WO2023107953A3 (en) Exon 1 frameshift antigens for vaccines, therapeutics, and diagnostics
Ateş et al. Is thyroid function associated with masked hypertension?
Korotyaev On new synonymy in the weevil subfamily Entiminae (Coleoptera: Curculionidae)
WO2016055161A3 (de) Verwendung von immunmodulatorisch wirksamen kits zur immuntherapeutischen behandlung von patienten mit myeloischen leukämien
Amadi et al. OCCURRENCE OF Yersinia enterocolitica SEROTYPE O: 9, AND Citrobacter freundii, TWO POTENTIAL HUMAN PATHOGENS IN THE THROATS OF TROPICAL PIGS OF GRENADA ORIGIN
Damento Adalimumab/infliximab